Azitra Inc (AZTR) - Net Assets
Based on the latest financial reports, Azitra Inc (AZTR) has net assets worth $3.80 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.03 Million) and total liabilities ($1.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Azitra Inc stock valuation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.80 Million |
| % of Total Assets | 75.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 33256.28 |
Azitra Inc - Net Assets Trend (2021–2025)
This chart illustrates how Azitra Inc's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Azitra Inc (2021–2025)
The table below shows the annual net assets of Azitra Inc from 2021 to 2025. See Azitra Inc (AZTR) balance sheet quality index to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.80 Billion | +66608.16% |
| 2024-12-31 | $5.70 Million | +95.61% |
| 2023-12-31 | $2.91 Million | +108.03% |
| 2022-12-31 | $-36.26 Million | -40.73% |
| 2021-12-31 | $-25.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Azitra Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4188701000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.07K | 0.00% |
| Other Components | $3.87 Billion | 101.80% |
| Total Equity | $3.80 Billion | 100.00% |
Azitra Inc Competitors by Market Cap
The table below lists competitors of Azitra Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Halo Technologies Holdings Ltd
AU:HAL
|
$3.31 Million |
|
WestKam Gold Corp
V:WKG
|
$3.31 Million |
|
Expion360 Inc
NASDAQ:XPON
|
$3.31 Million |
|
Coloseum Holding a.s.
PR:COLOS
|
$3.31 Million |
|
Beam Communications Holdings Ltd
AU:BCC
|
$3.30 Million |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
$3.30 Million |
|
Ostrom Climate Solutions Inc
V:COO
|
$3.30 Million |
|
British Smaller Companies Vct Plc
LSE:BSV
|
$3.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Azitra Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,698,298 to 3,801,230,000, a change of 3,795,531,702 (66608.2%).
- Net loss of 10,955,370 reduced equity.
- New share issuances of 9,033,322 increased equity.
- Other factors increased equity by 3,797,453,750.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.96 Million | -0.29% |
| Share Issuances | $9.03 Million | +0.24% |
| Other Changes | $3.80 Billion | +99.9% |
| Total Change | $- | 66608.16% |
Book Value vs Market Value Analysis
This analysis compares Azitra Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-425.93 | $0.20 | x |
| 2022-12-31 | $-599.41 | $0.20 | x |
| 2023-12-31 | $84.40 | $0.20 | x |
| 2024-12-31 | $10.04 | $0.20 | x |
| 2025-12-31 | $779.97 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Azitra Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-0.29%) is above the historical average (-109.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -8126.98% | 0.01x | 0.00x | $-6.36 Million |
| 2022 | 0.00% | -3760.69% | 0.04x | 0.00x | $-7.05 Million |
| 2023 | -387.34% | -1644.87% | 0.13x | 1.76x | $-11.58 Million |
| 2024 | -157.37% | -119.57% | 1.02x | 1.29x | $-9.54 Million |
| 2025 | -0.29% | 0.00% | 0.00x | 1.32x | $-391.08 Million |
Industry Comparison
This section compares Azitra Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $32,169,478
- Average return on equity (ROE) among peers: -63.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Azitra Inc (AZTR) | $3.80 Million | 0.00% | 0.32x | $3.30 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $144.14 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $26.76 Million | -148.34% | 1.40x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $20.69 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $9.96 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $5.07 Billion |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more